Sei Investments Co. Acquires 31,055 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Sei Investments Co. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 81.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 69,071 shares of the biopharmaceutical company’s stock after acquiring an additional 31,055 shares during the quarter. Sei Investments Co.’s holdings in Royalty Pharma were worth $1,821,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Ballentine Partners LLC boosted its stake in Royalty Pharma by 3.3% in the 1st quarter. Ballentine Partners LLC now owns 12,541 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 406 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its stake in Royalty Pharma by 10.8% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 9,097 shares of the biopharmaceutical company’s stock valued at $276,000 after purchasing an additional 887 shares during the period. Meeder Advisory Services Inc. boosted its stake in Royalty Pharma by 12.7% in the 2nd quarter. Meeder Advisory Services Inc. now owns 8,223 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 926 shares during the period. GAMMA Investing LLC boosted its stake in Royalty Pharma by 172.5% in the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,037 shares during the period. Finally, Versant Capital Management Inc boosted its stake in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,043 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $27.75 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The stock has a market capitalization of $16.47 billion, a P/E ratio of 20.71, a price-to-earnings-growth ratio of 4.17 and a beta of 0.46. The stock has a fifty day moving average of $27.95 and a 200-day moving average of $27.85.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a return on equity of 23.61% and a net margin of 30.08%. The business had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter in the prior year, the firm earned $0.85 EPS. On average, sell-side analysts expect that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were issued a $0.21 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.03%. Royalty Pharma’s payout ratio is presently 62.69%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on RPRX shares. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, September 17th. Morgan Stanley lifted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, The Goldman Sachs Group lifted their price objective on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.